Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)
- First Posted Date
- 2009-09-16
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 24
- Registration Number
- NCT00977600
- Locations
- 🇺🇦
Medical Sanitary Division #2, Kharkiv, Ukraine
Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 35
- Registration Number
- NCT00950911
- Locations
- 🇬🇧
Research Site, York, United Kingdom
A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 45
- Registration Number
- NCT00936988
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 769
- Registration Number
- NCT00925600
- Locations
- 🇺🇦
Research Site, Zaporizhzhya, Ukraine
Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 358
- Registration Number
- NCT00925587
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 69
- Registration Number
- NCT00902356
A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2013-11-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 15
- Registration Number
- NCT00887965
Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis
- First Posted Date
- 2009-03-31
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 9
- Registration Number
- NCT00872729
- Locations
- 🇺🇸
University of California San Diego Medical Center, San Diego, California, United States
"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 27
- Registration Number
- NCT00840333
AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2014-03-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 162
- Registration Number
- NCT00770848
© Copyright 2024. All Rights Reserved by MedPath